Iasocholine (Fluorocholine (18f) Chloride)

• Iasocholine is used in PET imaging to assess cancers and related metabolic activity.
• Oncologic PET imaging: visualizes metabolic activity of malignant tumors for detection and staging.
• Neuro‑oncology PET: evaluates choline metabolism in primary and metastatic brain lesions.
• Therapy response assessment: helps determine early response to anticancer treatments by comparing tracer uptake over time.

• Fluorocholine (18F) chloride is taken up by cells with high choline kinase activity and incorporated into phosphatidylcholine within cell membranes. The radiolabelled fluorine‑18 emits positrons that are detected by PET scanners, allowing clinicians to map regions of increased choline metabolism, which commonly correspond to proliferating tumor cells.

Administration of Iasocholine may be associated with a range of adverse reactions.

Common Side Effects

• Nausea or mild vomiting.
• Transient flushing or warmth sensation.
• Mild headache.
• Injection‑site pain or erythema.
• Temporary hypotension.
• Mild allergic skin reaction.

Serious or Rare Side Effects

• Anaphylaxis or severe hypersensitivity reaction.
• Severe hypotension or cardiovascular collapse.
• Radiation‑induced skin injury at the injection site.
• Renal toxicity in patients with pre‑existing impairment.
• Pulmonary embolism or severe respiratory distress.
• Cardiac arrhythmias.

• Prior to administration, several precautionary measures should be considered.
• Pregnancy: avoid unless essential, as fetal radiation exposure cannot be excluded.
• Breastfeeding: discontinue breastfeeding for an appropriate interval after administration.
• Renal impairment: assess renal function before use, as clearance may be reduced.
• Allergy to components: do not administer to patients with known hypersensitivity to the formulation.
• Radiation exposure: limit repeat scans to clinically justified intervals.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iasocholine can interact with other agents that influence imaging or physiological responses.

Major Interactions (Avoid)

• Concurrent use of other radiopharmaceuticals: may cause signal interference.
• High‑dose iodinated contrast agents: can alter tracer distribution.
• Chemotherapeutic drugs that modify choline metabolism: may affect uptake.

Moderate Interactions (Monitor Closely)

• Medications affecting liver function: monitor hepatic parameters.
• Drugs known to cause hypersensitivity: observe for enhanced allergic response.
• Beta‑blockers or antihypertensives: may mask cardiovascular reactions during imaging.